Results are in for a new depression drug trial, and they're cratering this stockByBruce GilPublishedJanuary 2, 2025
Read on1/2/25G/O Media may get a commissionG/O Media may get a commissionRead on1/2/25Last Chance: Lowest Pricing on the Galaxy Watch6 Ends SoonByMike FazioliPublishedJanuary 2, 2025
This is how airlines are dealing with the New Orleans terror attack chaosByMelvin BackmanPublishedJanuary 2, 2025
This state is leading the charge in fighting retail crime. Here's howByFrancisco VelasquezPublishedJanuary 2, 2025
Read on1/2/25G/O Media may get a commissionG/O Media may get a commissionRead on1/2/25Use Datafy Geolocation Data to Skip the Crowded Cliches this New YearByJoe TilleliPublishedJanuary 2, 2025
Trying Dry January? These celebrities have their own non-alcoholic drink brandsByMadeline FitzgeraldPublishedJanuary 2, 2025
Bankrupt Spirit Airlines is now worth less than its executives made in 2023ByMelvin BackmanPublishedJanuary 2, 2025
Elon Musk’s cryptic post sent another memecoin soaring — momentarilyByVinamrata ChaturvediPublishedJanuary 2, 2025
Apple is giving discounts on iPhones in China to compete with HuaweiByBritney NguyenPublishedJanuary 2, 2025
Tesla failed to meet its EV sales goals and Wall Street's expectationsByWilliam GavinUpdatedJanuary 2, 2025
Unity Software stock is gaining after Roaring Kitty's cryptic social media postByWilliam GavinUpdatedJanuary 2, 2025
Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get themByBruce GilPublishedJanuary 2, 2025
